Determined to avoid a repeat of the supply shortfalls that plagued early GLP-1 rollouts for obesity, Eli Lilly has amassed a sizable store of its oral weight loss candidate orforglipron. Specifically, Lilly had secured “pre-launch inventories” worth $1.5 billion as of Dec. 31, with most of that supply tied to its GLP-1 pill, the company said in an SEC filing.
And other health news from the Morning Rounds newsletter
Friday’s RFI sets a March 19 deadline for stakeholders to weigh in on what the government should consider when putting together its second attempt at a 340B rebate test run.
A new campaign for Astellas Pharma’s Izervay is aimed at opening retina specialists’ eyes to the unique role they play in their geographic atrophy patients’ lives.
Vertex expects $500 million in 2026 from new products outside of its flagship cystic fibrosis franchise. In 2025, those drugs delivered a combined total of $175.6 million.
The regulatory environment in the United States encountered by Moderna during the development of its COVID-19 vaccine bears little resemblance to what the company experienced earlier this week when the FDA refused to review its application for approval of its flu shot mRNA-1010. Mani Foroohar, M.D., of Leerink Partners, says that the decision reflects “how sharp the departure has been between the
It’s déjà vu all over again. Just as the IgA nephropathy space becomes increasingly crowded, Novartis aims to turn a statistical miss into a regulatory win.
America’s disease surveillance system is broken. Here’s how to replace it.
Pharmacy kiosks can expand access and convenience, but only when paired with pharmacist-led safeguards that ensure safe and coordinated medication use.
The AAP has become a leading opponent of MAHA and RFK Jr.'s vaccine agenda.
Late Thursday, PTC revealed that it withdrew its FDA application for Translarna in nonsense mutation Duchenne muscular dystrophy after receiving feedback on its filing from the regulator.
Fish oil’s cancer-fighting reputation may hinge on a little-known gene. Researchers discovered that omega-3s like EPA and DHA help curb colorectal cancer only when the enzyme ALOX15 is present. Without it, fish oil sometimes increased tumor growth in mice—especially DHA. The results suggest that not all supplements work the same way, and genetics could determine who truly benefits.
Messenger RNA specialist Moderna's R&D spend sunk by nearly a third last year, a drop attributed in part to the wind-down of major phase 3 respiratory trials.
Scientists at Cedars-Sinai have uncovered a surprising repair system in the spinal cord that could open new doors for treating paralysis, stroke, and diseases like multiple sclerosis. They found that special support cells called astrocytes—located far from the actual injury—spring into action after damage. These “lesion-remote astrocytes” send out a protein signal, CCN1, that reprograms immune cel
Bayer has cooked up the next phase of its “See Your Risks” campaign with celebrity chef Jeff Mauro. The drugmaker is offering people the chance to dine in Mauro’s immersive dark dining experience, the Heart to Heart Bistro—provided they complete its aspirin heart health risk assessment.
Microplastics and nanoplastics are now found everywhere on Earth, from ocean depths to agricultural soils and even inside the human body. Yet scientists still struggle to understand what these particles actually do once they enter living organisms. A new study proposes an innovative fluorescence-based strategy that could allow researchers to track microplastics in real time as they move, transform
A low-fat vegan diet—without cutting calories or carbs—may help people with type 1 diabetes significantly reduce how much insulin they need, and how much they spend on it. In a new analysis published in BMC Nutrition, participants following the plant-based plan lowered their daily insulin use by 28%, while those on a portion-controlled diet saw no meaningful change.
A robotic arm that moves too quickly can feel creepy. One that moves too slowly feels awkward and unhelpful. In a VR study, researchers found that AI-powered prosthetic arms were best accepted when they moved at a natural, human-like speed—about one second per reach. That sweet spot boosted feelings of control, comfort, and even trust in the robot.
A protein called HIF1 may be the missing link behind painful tendon injuries like jumper’s knee and tennis elbow. Researchers showed that high levels of HIF1 actually cause harmful changes that make tendons brittle and prone to pain. In experiments, turning the protein off protected tendons — even under heavy strain.
In an interview, Moderna President Stephen Hoge took questions on an FDA decision on the biotech's mRNA flu vaccine, as well as the impact on the company and others in…